Linaclotide IR Pellets
Linaclotide IR Pellets – Immediate-Release Pellet Platform Supporting Low-Dose GI Formulations. Rraynex Linaclotide IR Pellets are developed as an immediate-release multiparticulate system for pharmaceutical manufacturers working on low-dose gastrointestinal applications. The platform focuses on uniformity, flow and capsule filling consistency within the constraints of the existing product specification.
Product overview
Linaclotide IR formulation requires careful handling of low-dose characteristics and immediate-release behavior. Rraynex pellet processing emphasizes controlled particle size and blend uniformity to support reproducible capsule filling. Technical specifications are available upon request.
Key characteristics
- Immediate-release multiparticulate platform.
- Controlled particle characteristics for low-dose handling.
- Suitable for capsule and multiparticulate development.
- Technical support for formulation and commercial supply.
Product specifications
- Product
- Linaclotide IR Pellets
- Form
- immediate-release Pellets
- Therapeutic category
- Guanylate Cyclase-C Receptor Agonist
- Strength
- 290 mcg
- Grade
- IP / BP / USP / EP
- Pack size
- 25/50 kg
- Site certifications
- WHO-GMP, ISO 9001, ISO 14001
Detailed specifications, COA and technical documentation are shared on request.
Supply and enquiries
Rraynex supplies Linaclotide IR Pellets to pharmaceutical manufacturers, formulation developers and CDMOs in 25/50 kg packs with batch traceability. Send your quantity, grade and documentation needs through the enquiry form and the commercial team will reply with specifications and a quotation. Rraynex is a B2B supplier and does not sell to consumers.
Send product enquiry Browse all pellets Manufacturing capabilities